Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 7

1.

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, et al.

Nature. 1993 Jun 3;363(6428):458-60.

PMID:
8099202
2.

RET mutations in a large indian family with medullary thyroid carcinoma.

Mahesh DM, Nehru AG, Seshadri MS, Thomas N, Nair A, Pai R, Rajaratnam S.

Indian J Endocrinol Metab. 2014 Jul;18(4):516-20. doi: 10.4103/2230-8210.137508.

3.

Different RET gene mutation-induced multiple endocrine neoplasia type 2A in 3 Chinese families.

Liu Q, Tong D, Yuan W, Liu G, Yuan G, Lan W, Zhang D, Zhang J, Huang Z, Zhang Y, Jiang J.

Medicine (Baltimore). 2017 Jan;96(3):e5967. doi: 10.1097/MD.0000000000005967.

4.

The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.

Melillo RM, Cirafici AM, De Falco V, Bellantoni M, Chiappetta G, Fusco A, Carlomagno F, Picascia A, Tramontano D, Tallini G, Santoro M.

Am J Pathol. 2004 Aug;165(2):511-21.

5.

Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.

Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R, Richardson AL, Houghton C, Mulligan LM, Ponder BA, Robinson BG.

Cancer Res. 1996 Mar 15;56(6):1241-3.

6.

Familial prevalence and age of RET germline mutations: implications for screening.

Machens A, Dralle H.

Clin Endocrinol (Oxf). 2008 Jul;69(1):81-7. Epub 2008 Jul 1.

PMID:
18062802
7.

RET proto-oncogene mutations in French MEN 2A and FMTC families.

Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, Calmettes C, Modigliani E, Lenoir GM.

Hum Mol Genet. 1994 Nov;3(11):1939-43.

PMID:
7874109

Supplemental Content

Support Center